Wanting on the underlying holdings of the ETFs in our protection universe at ETF Channel, we’ve got in contrast the buying and selling value of every holding towards the typical analyst 12-month ahead goal value, and computed the weighted common implied analyst goal value for the ETF itself. For the First Belief NYSE Arca Biotechnology Index Fund ETF (Image: FBT), we discovered that the implied analyst goal value for the ETF primarily based upon its underlying holdings is $213.35 per unit.
With FBT buying and selling at a current value close to $169.81 per unit, that signifies that analysts see 25.64% upside for this ETF wanting by to the typical analyst targets of the underlying holdings. Three of FBT’s underlying holdings with notable upside to their analyst goal costs are Genmab A/S (Image: GMAB), Catalyst Prescribed drugs Inc (Image: CPRX), and Corcept Therapeutics Inc (Image: CORT). Though GMAB has traded at a current value of $20.17/share, the typical analyst goal is 81.89% increased at $36.69/share. Equally, CPRX has 50.84% upside from the current share value of $21.38 if the typical analyst goal value of $32.25/share is reached, and analysts on common predict CORT to succeed in a goal value of $74.90/share, which is 35.20% above the current value of $55.40. Beneath is a twelve month value historical past chart evaluating the inventory efficiency of GMAB, CPRX, and CORT:
Mixed, GMAB, CPRX, and CORT symbolize 10.54% of the First Belief NYSE Arca Biotechnology Index Fund ETF. Beneath is a abstract desk of the present analyst goal costs mentioned above:
| Identify | Image | Latest Value | Avg. Analyst 12-Mo. Goal | % Upside to Goal |
|---|---|---|---|---|
| First Belief NYSE Arca Biotechnology Index Fund ETF | FBT | $169.81 | $213.35 | 25.64% |
| Genmab A/S | GMAB | $20.17 | $36.69 | 81.89% |
| Catalyst Prescribed drugs Inc | CPRX | $21.38 | $32.25 | 50.84% |
| Corcept Therapeutics Inc | CORT | $55.40 | $74.90 | 35.20% |
Are analysts justified in these targets, or overly optimistic about the place these shares shall be buying and selling 12 months from now? Do the analysts have a sound justification for his or her targets, or are they behind the curve on current firm and trade developments? A excessive value goal relative to a inventory’s buying and selling value can replicate optimism in regards to the future, however may also be a precursor to focus on value downgrades if the targets had been a relic of the previous. These are questions that require additional investor analysis.
10 ETFs With Most Upside To Analyst Targets »
Additionally see:
MVT Average Annual Return
Institutional Holders of AUXO
PPHI Historical Stock Prices
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
